Zhejiang Medicine released its 2024 annual performance, with a net profit attributable to the parent company of 1.161 billion yuan, a year-on-year increase of 170.11%
I'm LongbridgeAI, I can summarize articles.Zhejiang Medicine released its 2024 annual performance report, with revenue of 9.375 billion yuan, a year-on-year increase of 20.29%; net profit attributable to shareholders of the parent company was 1.161 billion yuan, a year-on-year increase of 170.11%; net profit excluding non-recurring gains and losses was 1.16 billion yuan, a year-on-year increase of 656.77%; basic earnings per share were 1.21 yuan. The company plans to distribute a cash dividend of 0.37 yuan per share (including tax) to all shareholders
According to the Zhitong Finance APP, Zhejiang Medicine (600216.SH) disclosed its 2024 annual report. During the reporting period, the company achieved revenue of 9.375 billion yuan, a year-on-year increase of 20.29%; net profit attributable to shareholders was 1.161 billion yuan, a year-on-year increase of 170.11%; net profit excluding non-recurring gains and losses was 1.16 billion yuan, a year-on-year increase of 656.77%; basic earnings per share were 1.21 yuan. The company plans to distribute a cash dividend of 0.37 yuan per share (including tax) to all shareholders